Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | Chief Scientific Officer | March 20, 2023 | March 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date March 20, 2023 · Filed March 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2033-03-19 | Direct | 157,500 |
Reported balance
After 2023-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-20 · Grant · Acquired 157,500 · Balance 157,500 F1: 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2023 Filed Mar 22, 2023 17:23 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 157,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001728117-23-000028 · wf-form4_167952019155286.xml · derivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2033-03-19 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 09:22 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 6,029 | $1.10 | $6,619.84 |
DisclosureSEC source: 0001728117-23-000016 · wf-form4_167931855307436.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,263 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.08 to $1.10 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 17:21 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 157,500 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001728117-22-000114 · wf-form4_167062448909309.xml · derivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2032-12-06 F1 · derivative.exercise_date: One-third of the total number of shares subject to the option will vest on December 7, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 16:57 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 4,876 | $12.07 | $58,867.95 |
DisclosureSEC source: 0001728117-22-000090 · wf-form4_166673142835218.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,292 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.881 to $12.078 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold.Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 17:04 UTC Amendment | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 4,876 | $12.07 | $58,867.95 |
DisclosureSEC source: 0001728117-22-000094 · wf-form4a_166690466548859.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,292 F1 · kind: The Reporting Person's purchase of 6,934 shares of common stock at a price of $7.21 per share on July 15, 2022 was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the Reporting Person's sale of common stock reported herein and, to the extent of 2,058 shares, the Reporting Person's sale of common stock at a price of $8.278 per share on March 16, 2022. The Reporting Person has agreed top pay to the Issuer $18,558.51, which, together with the $7,351.42 previously paid to the Issuer on July 15, 2022, represents the full amount of the profit realized in connection with the short-swing transaction. F2 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $11.881 to $12.078 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold.Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 16:27 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 6,934 | $7.21 | $49,994.14 |
DisclosureSEC source: 0001728117-22-000065 · wf-form4_165791682751110.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,168 F1 · kind: The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 6,934 shares, with the Reporting Person's sale of 6,934 shares of common stock at a price ranging from $8.278 to $8.25 per share on July 1, 2022 and March 16, 2022. The Reporting Person paid to the Issuer $7,351.42, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 16:39 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 8,808 | $8.25 | $72,648.38 |
DisclosureSEC source: 0001728117-22-000053 · wf-form4_165705352176346.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,234 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.01 to 8.25 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| May 04, 2022 Filed May 5, 2022 18:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 1,262 | $7.20 | $9,086.40 |
DisclosureSEC source: 0001728117-22-000041 · wf-form4_165178888025620.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,042 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 17:03 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 5,002 | $8.28 | $41,406.56 |
DisclosureSEC source: 0001728117-22-000027 · wf-form4_164755094113540.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,304 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.27 to $8.41 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 16:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001728117-22-000011 · wf-form4_164184919646960.xml · derivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-01-05 F1 · derivative.exercise_date: One-third of the total number of shares subject to the option will vest on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 17:01 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 2,377 | $12.25 | $29,118.25 |
DisclosureSEC source: 0001728117-21-000098 · wf-form4_163528202672533.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,306 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 16:02 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000080 · wf-form4_162516967007694.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,683 F1 · shares: Represents a restricted stock unit award, which will vest on the first anniversary of the grant date in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:15 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 31,750 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001728117-21-000050 · wf-form4_162024930008740.xml · derivative · entry 2 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 31,750 shares Expires 2031-05-03 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on May 3, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:15 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 10,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000050 · wf-form4_162024930008740.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,683 F1 · shares: Represents a restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.